116 related articles for article (PubMed ID: 1691567)
1. Protective potential of hepatitis B virus antigens other than the S gene protein.
Gerlich WH; Deepen R; Heermann KH; Krone B; Lu XY; Seifer M; Thomssen R
Vaccine; 1990 Mar; 8 Suppl():S63-8; discussion S79-80. PubMed ID: 1691567
[TBL] [Abstract][Full Text] [Related]
2. Vaccine engineering: enhancement of immunogenicity of synthetic peptide vaccines related to hepatitis in chemically defined models consisting of T- and B-cell epitopes.
Tam JP; Lu YA
Proc Natl Acad Sci U S A; 1989 Dec; 86(23):9084-8. PubMed ID: 2480595
[TBL] [Abstract][Full Text] [Related]
3. Recombinant Semliki Forest virus vectors encoding hepatitis B virus small surface and pre-S1 antigens induce broadly reactive neutralizing antibodies.
Niedre-Otomere B; Bogdanova A; Skrastina D; Zajakina A; Bruvere R; Ose V; Gerlich WH; Garoff H; Pumpens P; Glebe D; Kozlovska T
J Viral Hepat; 2012 Sep; 19(9):664-73. PubMed ID: 22863271
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of the gene S and Pre-S domains in hepatitis B virions and HBsAg filaments.
Heermann KH; Kruse F; Seifer M; Gerlich WH
Intervirology; 1987; 28(1):14-25. PubMed ID: 2448264
[TBL] [Abstract][Full Text] [Related]
5. Co-expression of hepatitis B virus antigens by a non-defective adenovirus vaccine vector.
Ye WW; Mason BB; Chengalvala M; Cheng SM; Zandle G; Lubeck MD; Lee SG; Mizutani S; Davis AR; Hung PP
Arch Virol; 1991; 118(1-2):11-27. PubMed ID: 1828660
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis B virus core and e antigen: immune recognition and use as a vaccine carrier moiety.
Schödel F; Peterson D; Milich D
Intervirology; 1996; 39(1-2):104-10. PubMed ID: 8957676
[TBL] [Abstract][Full Text] [Related]
7. Yeast recombinant hepatitis B vaccine.
Hilleman MR
Infection; 1987; 15(1):3-7. PubMed ID: 2437037
[TBL] [Abstract][Full Text] [Related]
8. Identification of T cell epitopes on hepatitis B surface antigen.
Vento S
Ann Ist Super Sanita; 1991; 27(1):37-40. PubMed ID: 1720295
[TBL] [Abstract][Full Text] [Related]
9. Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccines.
Shouval D; Ilan Y; Adler R; Deepen R; Panet A; Even-Chen Z; Gorecki M; Gerlich WH
Vaccine; 1994 Nov; 12(15):1453-9. PubMed ID: 7533967
[TBL] [Abstract][Full Text] [Related]
10. [Immunogenicity and harmlessness in the newborn of a vaccine (GenHevac B) containing the antigens S and pre-S2].
Tron F; Soulié JC; Goudeau A; Devillier P; Saliou P
Bull Soc Pathol Exot; 1991; 84(5 Pt 5):901-5. PubMed ID: 1840243
[TBL] [Abstract][Full Text] [Related]
11. Expression of hepatitis B virus antigens in attenuated Salmonellae for oral immunization.
Schödel F; Will H
Res Microbiol; 1990; 141(7-8):831-7. PubMed ID: 2101472
[TBL] [Abstract][Full Text] [Related]
12. Recombinant hepatitis B core antigen carrying preS1 epitopes induce immune response against chronic HBV infection.
Chen X; Li M; Le X; Ma W; Zhou B
Vaccine; 2004 Jan; 22(3-4):439-46. PubMed ID: 14670326
[TBL] [Abstract][Full Text] [Related]
13. Expression and immunoactivity of chimeric particulate antigens of receptor binding site-core antigen of hepatitis B virus.
Yang HJ; Chen M; Cheng T; He SZ; Li SW; Guan BQ; Zhu ZH; Gu Y; Zhang J; Xia NS
World J Gastroenterol; 2005 Jan; 11(4):492-7. PubMed ID: 15641132
[TBL] [Abstract][Full Text] [Related]
14. Persistence of antibodies after immunization with a recombinant yeast-derived hepatitis B vaccine following two different schedules.
Scheiermann N; Gesemann M; Maurer C; Just M; Berger R
Vaccine; 1990 Mar; 8 Suppl():S44-6; discussion S60-2. PubMed ID: 2139282
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety in newborns of a new recombinant hepatitis B vaccine containing the S and pre-S2 antigens.
Soulié JC; Devillier P; Santarelli J; Goudeau A; Vermeulen P; Guellier M; Saliou P; Hillion AM; Tron F; Huchet J
Vaccine; 1991 Aug; 9(8):545-8. PubMed ID: 1837646
[TBL] [Abstract][Full Text] [Related]
16. Comparative immunogenicity in children of mammalian cell-derived recombinant hepatitis B vaccine and plasma-derived hepatitis B vaccine.
Coursaget P; Bringer L; Sarr G; Bourdil C; Fritzell B; Blondeau C; Yvonnet B; Chiron JP; Jeannée E; Guindo S
Vaccine; 1992; 10(6):379-82. PubMed ID: 1534640
[TBL] [Abstract][Full Text] [Related]
17. Recombinant adenovirus induces antibody response to hepatitis B virus surface antigen in hamsters.
Morin JE; Lubeck MD; Barton JE; Conley AJ; Davis AR; Hung PP
Proc Natl Acad Sci U S A; 1987 Jul; 84(13):4626-30. PubMed ID: 2955413
[TBL] [Abstract][Full Text] [Related]
18. [Detection of pre-S gene products in HBsAg carriers and in hepatitis B vaccines].
Gerken G; Manns M; Kyriatsoulis A; Hess G; Meyer zum Büschenfelde KH
Z Gastroenterol; 1988 Jul; 26(7):374-9. PubMed ID: 2851893
[TBL] [Abstract][Full Text] [Related]
19. Induction of protection level of anti-pre-S2 antibodies in humans immunized with a novel hepatitis B vaccine consisting of M (pre-S2 + S) protein particles (a third generation vaccine).
Kuroda S; Fujisawa Y; Iino S; Akahane Y; Suzuki H
Vaccine; 1991 Mar; 9(3):163-9. PubMed ID: 1828318
[TBL] [Abstract][Full Text] [Related]
20. Use of synthetic T-cell epitopes as immunogens to induce antibodies to hepatitis B components.
Milich DR; Thornton GB
Methods Enzymol; 1989; 178():634-59. PubMed ID: 2481218
[No Abstract] [Full Text] [Related]
[Next] [New Search]
